Show simple item record

dc.contributor.authorManzano-Moreno, Francisco Javier
dc.contributor.authorLuna Bertos, María Elvira De 
dc.contributor.authorToledano Osorio, Manuel 
dc.contributor.authorUrbano Arroyo, Paula
dc.contributor.authorRuiz Rodríguez, Concepción 
dc.contributor.authorToledano Pérez, Manuel 
dc.contributor.authorOsorio Ruiz, Raquel 
dc.date.accessioned2024-04-17T10:54:14Z
dc.date.available2024-04-17T10:54:14Z
dc.date.issued2023-12-22
dc.identifier.citationManzano-Moreno, F.J.; de Luna-Bertos, E.; Toledano-Osorio, M.; Urbano-Arroyo, P.; Ruiz, C.; Toledano, M.; Osorio, R. Biomimetic Collagen Membranes as Drug Carriers of Geranylgeraniol to Counteract the Effect of Zoledronate. Biomimetics 2024, 9, 4. https://doi.org/10.3390/biomimetics9010004es_ES
dc.identifier.urihttps://hdl.handle.net/10481/90833
dc.description.abstractTo counteract the effect of zoledronate and decrease the risk of osteonecrosis of the jaw (BRONJ) development in patients undergoing guided bone regeneration surgery, the use of geranylgeraniol (GGOH) has been proposed. Collagen membranes may act as biomimetical drug carriers. The objective of this study was to determine the capacity of collagen-based membranes doped with GGOH to revert the negative impact of zoledronate on the growth and differentiation of human osteoblasts. MG-63 cells were cultured on collagen membranes. Two groups were established: (1) undoped membranes and (2) membranes doped with geranylgeraniol. Osteoblasts were cultured with or without zoledronate (50 μM). Cell proliferation was evaluated at 48 h using the MTT colorimetric method. Differentiation was tested by staining mineralization nodules with alizarin red and by gene expression analysis of bone morphogenetic proteins 2 and 7, alkaline phosphatase (ALP), bone morphogenetic proteins 2 and 7 (BMP-2 and BMP-7), type I collagen (Col-I), osterix (OSX), osteocalcin (OSC), osteoprotegerin (OPG), receptor for RANK (RANKL), runt-related transcription factor 2 (Runx-2), TGF-β1 and TGF-β receptors (TGF-βR1, TGF-βR2, and TGF-βR3), and vascular endothelial growth factor (VEGF) with real-time PCR. One-way ANOVA or Kruskal–Wallis and post hoc Bonferroni tests were applied (p < 0.05). Scanning electron microscopy (SEM) observations were also performed. Treatment of osteoblasts with 50 μM zoledronate produced a significant decrease in cell proliferation, mineralization capacity, and gene expression of several differentiation markers if compared to the control (p < 0.001). When osteoblasts were treated with zoledronate and cultured on GGOH-doped membranes, these variables were, in general, similar to the control group (p > 0.05). GGOH applied on collagen membranes is able to reverse the negative impact of zoledronate on the proliferation, differentiation, and gene expression of different osteoblasts’ markers.es_ES
dc.description.sponsorshipGrant PID2020-114694RB-I00 funded by MCIN/AEI 10.13039/501100011033es_ES
dc.description.sponsorshipFPU of Ministry of Universities [grant FPU20/00450]es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectZoledronatees_ES
dc.subjectCollagen membraneses_ES
dc.subjectOsteoblastes_ES
dc.titleBiomimetic Collagen Membranes as Drug Carriers of Geranylgeraniol to Counteract the Effect of Zoledronatees_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/biomimetics9010004
dc.type.hasVersionVoRes_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional